Synthesis, physicochemical characterization and preliminary pharmacological in vitro evaluation of two novel cytotoxic benzophenone-linked 3,3-dimethyltriazenes

Pharmazie

Volumn 61, Issue 6, 2006, Pages 511-516

  Manolov, Ilia ^a   Machulla, H J ^b   Momekov, G ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BENZOYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (2 HYDROXYMETHYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (2 NITROPHENYL) 3,3 DINETHYLTRIAZENE; 1 (3 ACETYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (3 HYDROXYMETHYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (3 NITROPHENYL) 3,3 DINETHYLTRIAZENE; 1 (4 ACETYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (4 BENZOYLPHENYL) 3,3 DIMETHYLTRIAZENE; 1 (4 HYDROXYMETHYLPHENYL) 3,3 DINETHYLTRIAZENE; 1 (4 NITROPHENYL) 3,3 DINETHYLTRIAZENE; 1 (P TOLYL) 3,3 DINETHYLTRIAZENE; 3,3 DIMETHYL 1 PHENYLTRIAZENE; ALKYLATING AGENT; BENZOPHENONE; DNA FRAGMENT; MELPHALAN; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL STRAIN HL 60; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA DETERMINATION; DRUG ANALYSIS; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PROMYELOCYTIC LEUKEMIA; STAINING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOPHENONES; CELL LINE; CHEMISTRY, PHYSICAL; DNA FRAGMENTATION; DNA, NEOPLASM; HL-60 CELLS; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES; TRIAZENES;

EID: 33745593089     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bagrij T, Klokouzas A, Hladky SB, Barrand MA (2001) Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem Pharmacol 62: 199-206.
2. Clarke DA, Barkley RK, Stock CC, Rondestvedt CS Jr. (1955) Triazenes as inhibitors of mouse sarcoma 180. Proc Soc Exptl Biol Med 90: 484-489.
3. Connors TA, Goddard PM, Merai K, Ross WCJ, Wilman DEV (1976) Tumour inhibitory triazenes: Structural requirements for an active metabolite. Biochem Pharmacol 25: 241-246.
4. O'Connor PM, Kohn KW (1992) A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol 3: 409-416.
5. Diaz-Carballo D, Seeber S, Strumberg D, Hilger RA (1994) Novel antitumoral compound isolated from Clusia rosea. Int J Clin Pharmacol Ther 41: 622-623.
6. Foster BJ (1998) Procarbazine, Dacarbazine, Temozolomide in A Clinician's Guide to Chemotherapy Pharmakokinetics and Pharmacodynamics (Ed.: LB Grochow, MM Ames) Williams & Wilkins, Baltimore, MD, USA.
7. Gescher A, Hickman JA, Simmonds RJ, Steves MFG, Vaughan K (1981) Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenes. Biochem Pharmacol 30: 89-93.
8. Kearns PR, Hall AG (1998) Glutathione and the response of malignant cells to chemotherapy. Drug Discor Today 3: 113-121.
9. Kohn EC, Felder CC, Jacobs W, Holmes KA, Day A, Freer R, Liotta LA (1994) Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 54: 935-942.
10. Konstantinov S M, Eibl H, Berger M R (1999) BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. Br J Haematol 107: 365-374.
11. Liou JP, Chang JY, Chang CW, Chang CY, Mahindroo N, Kuo FM, Hsieh HP (2004) Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J Med Chem 47: 4247-4257.
12. Matheson SL, McNamee JP, Jean-Claude BJ (2003) Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 51: 11-20.
13. Matheson SL, McNamee J, Jean-Claude BJ (2001) Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 296: 832-40.
14. Matsumoto K, Akao Y, Kobayashi E, Ito T, Ohguchi K, Tanaka T, Iinuma M, Nozawa Y (2003) Cytotoxic benzophenone derivatives from Garcinia species display a strong apoptosis-inducing effect against human leukemia cell lines. Biol Pharm Bull 26: 569-571.
15. Mitsch A, Bergemann S, Gust R, Sattler I, Schlitzer M (2003) Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue famesyltransferase inhibitors. Arch Pharm (Weinheim) 336: 242-250.
16. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
17. Schwartzman RA, Cidlowski JA (1993) Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev 14: 133-151.
18. Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncology 2001 2: 552-560.
19. Threadgill MD, Stevens MFG (1983) Selective reactions in the triazene series. I. Reduction of 1-(4-acetylphenyl)-triazenes. Synthesis 4: 289-291.